SynthesisPediatrics2019
Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review.
Synthesis in Pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vaccination of Adults With Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Guideline
- Safety, immunogenicity, and effectiveness of the MAV/06 varicella vaccine: A comprehensive review of a new strain vaccine.Human vaccines & immunotherapeutics · 2026Review
- A Stepwise Household Transmission of Vaccine-Strain Varicella-Zoster Virus Resulting in Neonatal Varicella.Infection & chemotherapy · 2026Article
- The Role of Vaccination in Adult Solid Organ Transplantation: Updated Reviews with Recent Guidelines.Microorganisms · 2026Review
- A Short Review and Update on Epidemiology, Treatment, and Management of Herpes Zoster (Shingles) Infection.Current pharmaceutical design · 2026Review
- Article
- Perspectives on the History and Epidemiology of the Varicella Virus Vaccine and Future Challenges.Pathogens (Basel, Switzerland) · 2025Review
- Genomic analysis of Varicella zoster virus strains during an outbreak with atypical clinical presentations in Biswanath district of Assam, India.Virus genes · 2025Article
- Review
- Disseminated vaccine-strain varicella-zoster virus reactivation in an adolescent with secondary immunodeficiency: a case report and literature review.BMC infectious diseases · 2024Review
- Vaccine-Associated Measles in an Immunocompromised Host: Hospital Infection Prevention and Control and Public Health Response.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024Article
- Creating the "Dew Drop on a Rose Petal": the Molecular Pathogenesis of Varicella-Zoster Virus Skin Lesions.Microbiology and molecular biology reviews : MMBR · 2023Review
- Use of Mpox Multiplex Serology in the Identification of Cases and Outbreak Investigations in the Democratic Republic of the Congo (DRC).Pathogens (Basel, Switzerland) · 2023Article
- Prodrug Strategies for the Development of β-l-5-((Journal of medicinal chemistry · 2023Article
- Varicella in the neonatal ICU due to the Varicella vaccine Oka strain.Journal of neonatal-perinatal medicine · 2023Article
- Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.The Journal of infectious diseases · 2022Review
- Insights From Studies of the Genetics, Pathogenesis, and Immunogenicity of the Varicella Vaccine.The Journal of infectious diseases · 2022Article
- Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster.The Journal of infectious diseases · 2021Article
- Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
contextLive vaccines usually provide robust immunity but can transmit the vaccine virus.
objectiveTo assess the characteristics of secondary transmission of the vaccine-strain varicella-zoster virus (Oka strain; vOka) on the basis of the published experience with use of live varicella and zoster vaccines. DATA SOURCES: Systematic review of Medline, Embase, the Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, and Scopus databases for articles published through 2018. STUDY SELECTION: Articles that reported original data on vOka transmission from persons who received vaccines containing the live attenuated varicella-zoster virus. DATA EXTRACTION: We abstracted data to describe vOka transmission by index patient's immune status, type (varicella or herpes zoster) and severity of illness, and whether transmission was laboratory confirmed.
resultsTwenty articles were included. We identified 13 patients with vOka varicella after transmission from 11 immunocompetent varicella vaccine recipients. In all instances, the vaccine recipient had a rash: 6 varicella-like and 5 herpes zoster. Transmission occurred mostly to household contacts. One additional case was not considered direct transmission from a vaccine recipient, but the mechanism was uncertain. Transmission from vaccinated immunocompromised children also occurred only if the vaccine recipient developed a rash postvaccination. Secondary cases of varicella caused by vOka were mild. LIMITATIONS: It is likely that other vOka transmission cases remain unpublished.
conclusionsHealthy, vaccinated persons have minimal risk for transmitting vOka to contacts and only if a rash is present. Our findings support the existing recommendations for routine varicella vaccination and the guidance that persons with vaccine-related rash avoid contact with susceptible persons at high risk for severe varicella complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.